CIK 0001880438
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
AN2 Therapeutics, Inc.
Sign in to watch- Ticker
- ANTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 820606654
- Phone
- +1 650-331-9090
- Business address
- 1300 EL CAMINO REAL, SUITE 100, MENLO PARK, CA, 94025
- Open-market buys, last 90 days
- $11,602
- in 1 filing
- Open-market sales, last 90 days
- $117,428
- in 4 filings, $104K under 10b5-1 plans
Net −$105,826. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-15 | Eckburg Paul Chief Medical Officer | Grant or award | +30,000 | 51,416 | ||
| 2024-03-15 | Day Lucy Chief Financial Officer | Grant or award | +27,500 | 30,627 | ||
| 2024-03-15 | Eizen Joshua M Chief Legal Officer | Grant or award | +30,000 | 32,447 | ||
| 2024-03-15 | Krause Kevin Michael Chief Strategy Officer | Grant or award | +30,000 | 31,914 | ||
| 2024-03-15 | Chanda Sanjay Chief Development Officer | Grant or award | +27,500 | 28,235 | ||
| 2024-03-15 | Easom Eric Chief Executive Officer | Grant or award | +99,000 | 101,130 | ||
| 2024-03-15 | Day Lucy Chief Financial Officer | Grant or award | +27,500 | 30,627 | ||
| 2024-03-15 | Day Lucy Chief Financial Officer | Grant or award · Stock Option (right to buy) | +55,000 | 55,000 | ||
| 2024-03-15 | Eizen Joshua M Chief Legal Officer | Grant or award | +30,000 | 32,447 | ||
| 2024-03-15 | Eizen Joshua M Chief Legal Officer | Grant or award · Stock Option (right to buy) | +60,000 | 60,000 | ||
| 2024-03-15 | Krause Kevin Michael Chief Strategy Officer | Grant or award | +30,000 | 31,914 | ||
| 2024-03-15 | Krause Kevin Michael Chief Strategy Officer | Grant or award · Stock Option (right to buy) | +60,000 | 60,000 | ||
| 2024-03-15 | Chanda Sanjay Chief Development Officer | Grant or award | +27,500 | 28,235 | ||
| 2024-03-15 | Chanda Sanjay Chief Development Officer | Grant or award · Stock Option (right to buy) | +55,000 | 55,000 | ||
| 2024-03-15 | Eckburg Paul Chief Medical Officer | Grant or award | +30,000 | 51,416 | ||
| 2024-03-15 | Eckburg Paul Chief Medical Officer | Grant or award · Stock Option (right to buy) | +60,000 | 60,000 | ||
| 2024-03-15 | Easom Eric Chief Executive Officer | Grant or award | +99,000 | 101,130 | ||
| 2024-03-15 | Easom Eric Chief Executive Officer | Grant or award · Stock Option (right to buy) | +198,000 | 198,000 | ||
| 2024-01-18 | Zakrzewski Joseph S Director | Sale | −100,000 | $19.11 | $1.9M | 405,880 |
| 2024-01-16 | Aziz Kabeer Director | Sale | −84,093 | $19.65 | $1.7M | 1,995,958 |
Page 11 of 20 · 385 trades